Patient Access to Clinical Trials in the UK

This podcast is initiated, organised and funded by Merck Serono Ltd. Merck Serono Ltd is a pharmaceutical company.

Nearly 80% of clinical trials fail to adequately recruit participants on proposed timelines negatively impacting patient access to new treatments[i]. Patient recruitment in clinical trials is imperative for a successful study and delays, or low participant numbers, can prevent patients accessing the newest and most innovative treatments.

In this episode our UK & ROI Director of Market Access, Pricing and Government & Public Affairs, Tina Alexopoulos, sat down with Lesley Caldow, Head of In-Country Study Operations at Merck UK & ROI, Sharon Brenan, Director of Policy and External Affairs at National Voices, and Dr Mohini Varughese, Consultant Clinical Oncologist at Royal Devon University Hospitals NHS Foundation Trust and Honorary Clinical Associate Professor for the University of Exeter, to discuss the barriers patients face in accessing clinical trials, whether these are practical, attitudinal, or communicable, and how these can be overcome.

UI-NONO-00532 | February 2025

 

 

[i] Perspectives in Clinical Research,Recruitment and retention of participants in clinical studies: Critical issues and challenges - PMC , accessed December 2024